Business Context and Reporting Period
Kura Oncology, Inc., a Delaware corporation and emerging growth company, filed this Form 8-K on March 5, 2019. The report details the entry into a material definitive agreement to establish an "at-the-market" (ATM) equity offering program.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the authorization to sell up to $75,000,000 of common stock. The company will pay the sales agents a commission of up to 3.0% of gross sales proceeds.
Material Changes
The material change reported is the execution of a sales agreement with SVB Leerink LLC and Stifel, Nicolaus & Company, Incorporated. This agreement allows the company to sell shares of its common stock through the agents as sales agents at market prices prevailing at the time of sale. The company is not obligated to make any sales under this agreement.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or management commentary on future operational outlook. The offering is subject to termination upon the sale of all shares or termination of the agreement. The company notes that the offering will be conducted pursuant to its shelf registration statement on Form S-3. No specific risks or contingencies beyond standard securities law disclaimers are detailed in this text.
Investor Verification Checklist
- Verify the current market price of Kura Oncology common stock to assess the potential dilution impact of the $75 million ATM program.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific conditions or limitations on sales.
- Check the company's most recent 10-K or 10-Q filings for current cash position and liquidity needs driving this capital raise.
- Confirm the status of the shelf registration statement (File No. 333-228172) referenced in the filing.